Dr. Idell received his medical degree from Temple University in 1977, where he did his residency in internal medicine and pulmonary medicine and joined the pulmonary faculty in 1983 as an Assistant Professor. He then joined the faculty of the University of Texas Health Science Center at Tyler in 1984, where he served as Chief of the Pulmonary Division, Chair of the Department of Medical Specialties and now serves as Senior Vice President for Research and Dean of the School of Medical Biological Sciences. He is a Professor of Medicine and Temple Chair of Pulmonary Fibrosis as a member of the faculty.
The laboratory focus is in the areas of fibrin turnover in lung and pleural injury and includes investigation of the role of cellular differentiation, matrix deposition and organization in the pathogenesis of these disorders. The targeting of key components of pathways of fibrin turnover has led to identification of new interventions for pleural organization/loculation and for pulmonary fibrosis, which are being commercialized via a UT System and privately funded biotechnology start-up called Lung Therapeutics, Inc. The commercialization process involves a model that leverages NIH funding from various NHLBI sources with the resources of the company to move product development forward.
<strong>Major Areas of Research</strong>
<li>Lung and pleural injury and repair</li>
<li>Coagulation and fibrinolysis</li>
My group has had a long-standing interest in the area of pulmonary fibrosis as well as acute lung and pleural injury and will continue my long-standing collaboration with UTHSCT and external collaborators on our active projects. I have an interest in product development for challenging pulmonary disorders and am also a PI on an NIH NHLBI SMARTT contract to manufacture single chain urokinase plasminogen activator (scuPA), perform toxicologic studies for the intrapleural use of scuPA and provide regulatory support in anticipation of clinical trial testing of intrapleural use of scuPA for patients with complicated parapneumonic pleural effusions (CPE) or empyema associated with pneumonia. I also serve on the advisory board of the NHLBI VITA program, which is another translational effort to address vascular disorders with new interventional approaches. I am also very interested in the training and career development of young people interested in the sciences and address this as a top priority area. As another priority, I maintain an active clinical practice focused on pulmonary medicine. I have served on numerous NIH review panels including IPF Net and continue to offer the service whenever possible.
Marudamuthu AS, Shetty SK, Bhandary YP, Karandashova S, Thompson M, Sathish V, Florova G, Hogan TB, Pabelick CM, Prakash YS, Tsukasaki Y, Fu J, Ikebe M, Idell S, Shetty S. Plasminogen activator inhibitor-1 suppresses pro-fibrotic responses in fibroblasts from fibrotic lungs. J Biol Chem. 2015 Feb 3. pii: jbc.M114.601815. [Epub ahead of print]. PMID: 25648892
Gan H, McKenzie R, Hao Q, Idell S, Tang H. Protein kinase D is increased and activated in lung epithelial cells and macrophages in idiopathic pulmonary fibrosis. PLoS One. 2014 Jul 7;9(7):e101983. doi: 10.1371/journal.pone.0101983. eCollection 2014. PMID 25000413
Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Idell S, listed author. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. Idiopathic Pulmonary Fibrosis Clinical Research Network. N Engl J Med. 2014 May 29;370(22):2093-101. doi: 10.1056/NEJMoa1401739. Epub 2014 May 18. PMID: 24836309
Bhandary YP, Shetty SK, Marudamuthu AS, Ji HL, Neuenschwander PF, Boggaram V, Morris GF, Fu J, Idell S, Shetty S. Regulation of lung injury and fibrosis by p53-mediated changes in urokinase and plasminogen activator inhibitor-1. Am J Pathol. 2013 Jul;183(1):131-43. doi: 10.1016/j.ajpath.2013.03.022. Epub 2013 May 8. PMID 23665346
Jeffers A, Owens S, Koenig K, Quaid B, Pendurthi UR, Rao LV, Idell S, Tucker TA. Thrombin Down-Regulates Tissue Factor Pathway Inhibitor Expression in a PI3K/NFκB-Dependent Manner in Human Pleural Mesothelial Cells. Am J Respir Cell Mol Biol. 2014 Oct 10. [Epub ahead of print]. PMID:25303460
Florova G, Azghani A, Karandashova S, Schaefer C, Koenig K, Stewart-Evans K, Declerck PJ, Idell S, Komissarov AA. Targeting of Plasminogen Activator Inhibitor 1 Improves Fibrinolytic Therapy for Tetracycline Induced Pleural Injury in Rabbits. Am J Respir Cell Mol Biol. 2014 Aug 20. [Epub ahead of print] PMID: 25140386
Colice G, Idell S. Rebuttal from Drs Colice and Idell. Chest. 2014 Jan;145(1):21-3. doi: 10.1378/chest.13-2357. No abstract available. PMID: 24394819
L Colice G, Idell S. Counterpoint: should fibrinolytics be routinely administered intrapleurally for management of a complicated parapneumonic effusion? No. Chest. 2014 Jan;145(1):17-20. doi: 10.1378/chest.13-2356. No abstract available. PMID: 24394817
Tucker TA, Jeffers A, Alvarez A, Owens S, Koenig K, Quaid B, Komissarov AA, Florova G, Kothari H, Pendurthi U, Rao LV, Idell S. Plasminogen activator inhibitor-1 deficiency augments visceral mesothelial organization, intrapleural coagulation and lung restriction in mice with carbon black/bleomycin-induced pleural injury. Am J Respir Cell Mol Biol. 2013 Sep 11. [Epub ahead of print]
Komissarov AA, Florova G, Azghani A, Karandashova S, Kurdowska AK, Idell S. Active α-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids. Am J Physiol Lung Cell Mol Physiol. 2013 Aug 30. [Epub ahead of print]
Florova G, Karandashova S, Declerck PJ, Idell S, Komissarov AA. Remarkable Stabilization of Plasminogen Activator Inhibitor 1 in a "Molecular Sandwich" Complex. Biochemistry. 2013 Jun 25. [Epub ahead of print]
Tucker T, Idell S. Plasminogen-plasmin system in the pathogenesis and treatment of lung and pleural injury. Semin Thromb Hemost. 2013 Jun;39(4):373-81. doi: 10.1055/s-0033-1334486. Epub 2013 Mar 16. PMID: 23504608
Komissarov AA, Stankowska D, Krupa A, Fudala R, Florova G, Florence J, Fol M, Allen TC, Idell S, Matthay MA, Kurdowska AK. Novel aspects of urokinase function in the injured lung: role of α2-macroglobulin. Am J Physiol Lung Cell Mol Physiol. 2012 Dec 15;303(12):L1037-45. doi: 10.1152/ajplung.00117.2012. Epub 2012 Oct 12. PMID: 23064953
Karandashova S, Florova G, Azghani AO, Komissarov AA, Koenig K, Tucker TA, Allen TC, Stewart K, Tvinnereim A, Idell S. Intrapleural adenoviral delivery of human plasminogen activator inhibitor-1 exacerbates tetracycline-induced pleural injury in rabbits. Am J Respir Cell Mol Biol. 2013 Jan;48(1):44-52. doi: 10.1165/rcmb.2012-0183OC. Epub 2012 Sep 20. PMID: 23002099
Tucker TA, Williams L, Koenig K, Kothari H, Komissarov AA, Florova G, Mazar AP, Allen TC, Bdeir K, Mohan Rao LV, Idell S. Lipoprotein receptor-related protein 1 regulates collagen 1 expression, proteolysis, and migration in human pleural mesothelial cells. Am J Respir Cell Mol Biol. 2012 Feb;46(2):196-206. doi: 10.1165/rcmb.2011-0071OC. PMID: 22298529
Komissarov AA, Florova G, Idell S. Effects of extracellular DNA on plasminogen activation and fibrinolysis. J Biol Chem. 2011 Dec 9;286(49):41949-62. doi: 10.1074/jbc.M111.301218. Epub 2011 Oct 5. PMID: 21976662
Williams L, Tucker TA, Koenig K, Allen T, Rao LV, Pendurthi U, Idell S. Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice. Am J Respir Cell Mol Biol. 2012 Feb;46(2):173-9. doi: 10.1165/rcmb.2010-0276OC. Epub 2011 Aug 18. PMID: 21852688
Idell S, Jun Na M, Liao H, Gazar AE, Drake W, Lane KB, Koenig K, Komissarov A, Tucker T, Light RW. Single-chain urokinase in empyema induced by Pasturella multocida. Exp Lung Res. 2009 Oct;35(8):665-81. doi: 10.3109/01902140902833277. PMID: 19895321
Shetty S, Velusamy T, Shetty RS, Marudamuthu AS, Shetty SK, Florova G, Tucker T, Koenig K, Shetty P, Bhandary YP, Idell S. Post-transcriptional regulation of plasminogen activator inhibitor type-1 expression in human pleural mesothelial cells. Am J Respir Cell Mol Biol. 2010 Sep;43(3):358-67. doi: 10.1165/rcmb.2009-0046OC. Epub 2009 Oct 23. PMID: 19855086
Komissarov AA, Mazar AP, Koenig K, Kurdowska AK, Idell S. Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits. Am J Physiol Lung Cell Mol Physiol. 2009 Oct;297(4):L568-77. doi: 0.1152/ajplung.00066.2009. Epub 2009 Aug 7. PMID: 19666776
Ongoing Research Support
Idell (Contact) Enkhebataar, Wolfson and Williams
Airway Delivery of Fibrinolytic Therapy for ISALI.</strong>
The goal of this project is to determine if fibrinolysins delivered in either and aersol or perfluorocarbon vehicle can reverse airway fibrin and organization in inhalational cotton-smoke induced acute lung injury.
09/2011 – completion
scuPA for the Treatment of Complicated Parapneumonic Effusions
The NHLBI Science Moving towArds Research Translation and Therapy program (SMARTT) contract facilitates the translation of novel discoveries into successful new therapies for heart, lung, and blood diseases. Support for cGMP manufacturing, GLP-compliant pharmacology/toxicology IND-enabling studies and regulatory support is provided for an IND submission for the zymogen form of urokinase, scuPA. (No specified end date).
Recently Completed Research Support
Idell S (Contact PI); Komissarov A (Co-PI)
05/01/2011 - 04/30/2014
PAI-1 Targeted Intrapleural Fibrinolytic Therapy.
The primary goals of this project are to test various strategies that target plasminogen activator inhibitor-1 (PAI-1) in the preclinical treatment of pleural loculation. The objective of this work is to determine if PAI-1-targeted approaches confer advantages that are of potential clinical benefit over current pharmacologic approaches in anticipation of future clinical trial testing of PAI-1 targeted interventions that prove to be effective in our models of pleural injury.
Liu, G. (PI)
01/25/2010 - 01/31/2014
Urokinase, Neutrophil Activation and Acute Lung Injury
The primary goals of this project are to investigate the mechanisms through which urokinase, particularly the kringle domain of urokinase, induces neutrophil activation and in vivo proinflammatory responses that lead to acute lung injury. Interactions between urokinase, the urokinase kringle domain, plasmin, and plasminogen activator inhibitor 1 that lead to neutrophil activation will also be explored. The project does not address oxidative stress, hemorrhage, oxidants, nor PI3-K, and has no overlap with the present application.
NIH PO1 HL
Idell S (PI, PD)
Fibrinolytic Pathways in Lung Injury and Repair
This project will elucidate novel pathways by which the fibrinolytic system influences acute injury and repair in the lung and pleural compartment.
Idell S (PI)
01/01/2009 - 01/31/2012
IND-enabling toxicology, pharmacology and safety studies of recombinant scuPA for treatment of
This is a grant to perform toxicology studies on scuPA, a drug that will be prepared for clinical trial testing through work done as part of this grant.